SSO would like to thank the following companies for their support. Please select a name to learn more.
Who we are
The ACPMP Research Foundation is an IRS-designated 501(c)3 charitable organization (EIN: 26-2890160). The Foundation was created in 2008 by a community of individuals affected by Pseudomyxoma Peritonei (PMP), Appendix Cancer, and related Peritoneal Surface Malignancies (PSM).
What we do
ACPMP is dedicated to (1) funding research to find a cure for Pseudomyxoma Peritonei (PMP), Appendix Cancer, and related Peritoneal Surface Malignancies (PSM), and (2) funding educational programs to educate physicians and patients about these diseases.
Belmont Medical Technologies is a leading provider of fluid management and patient temperature management solutions for use worldwide in medical facilities, military, and EMS settings.
Hyperthermia Pump™ is used in therapeutic procedures to raise the temperature of the thoracic or peritoneal cavity to the desired target temperature by continuously lavaging the cavity with warmed sterile solution. The warm solution is pumped into a body cavity, withdrawn, reheated, and recirculated back to the body. To ensure safe operation, the system monitors line pressure and air in the fluid path while two sterile temperature probes located within the sterile field and two embedded temperature probes monitor patient cavity, outflow solution, and return solution temperature. The Hyperthermia Pump’s disposables are aluminum-free. Belmont offers various configurations – Straight Line or Bifurcated Line Sets, and Cannula Connectors. Additionally, Belmont offers a Procedure Pack designed to save time and money by simplifying complicated tubing setups into a single, comprehensive and easy to install kit.
Belmont’s advanced targeted temperature solution Allon®, with ThermoWrap® patient garment, is designed to allow healthcare providers to precisely control and manage patient body temperature. Core and surface temperature sensors provide continuous patient temperature feedback to enable thermal monitoring and regulation.
Intera Oncology is a rapidly growing Boston-based life science company on a mission to change the course of cancer for patients with metastatic colorectal cancer and cholangiocarcinoma. The Intera 3000 Hepatic Artery Infusion Pump is a palm-sized, implantable device that delivers a continuous flow of therapy directly to metastatic tumors in the liver. This allows patients to receive therapy while going about their normal daily activities outside of a hospital with minimal disruption to their lives.
The Intera Oncology team is comprised of individuals who are passionate about making a difference by making the company’s treatment available to any patient who can benefit. The organization is also developing innovative new solutions to address other diseases with significant unmet needs. Learn more at interaoncology.com and follow Intera on Twitter, LinkedIn and Facebook.
Iovance Biotherapeutics
aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to fighting cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
“Bold thinking. Bolder actions. We are Medtronic.
We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world.
In everything we do, we are engineering the extraordinary.”
PMP Pals is the world’s oldest global support group for patients fighting Cancer of the Appendix and Pseudomyxoma Peritonei. PMP Pals offers hope and support for patients and caregivers through a variety of free programs, including one-on-one mentoring, patient education and networking opportunities among patients and caregivers. Visit pmppals.net to learn more. Our mantras, “You are not Alone” and “We have hope for you” provide encouragement and strength to our patient community.
Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.
Replimune’s tumor directed oncolytic immunotherapies belong to a novel class of cancer therapeutics and are designed with a dual mechanism of action. Replimune treatments work by directly destroying tumors and altering the tumor microenvironment (TME), thereby releasing tumor derived antigens in an immuno-stimulatory fashion. This induces a powerful and durable systemic immune response against a patient’s own cancer.
While oncolytic immunotherapies have shown clinical activity against tumors when given as single agents, we expect these therapies to combine with and enhance the effectiveness of several different modalities and treatments — including immunotherapy, chemotherapy, small molecules and radiation — because of the synergistic MOA and well-established safety profile.
Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.
Our current lead product is a targeted radiation therapy for liver tumors called SIR-Spheres® Y-90 resin microspheres.
ThermaSolutions is the global leader in Hyperthermic Medical Technology. We have established and will continue our leadership through extensive research, development and product innovation.
One such product innovation is the ThermaSolutions HurriChem™, for laparoscopic procedures. Newly FDA-approved, HurriChem™ uses an aerosolizing irrigation wand and braided poly tubing. It is a single- use device used to deliver aerosolized fluids to surgical sites during laparoscopic procedures.
ThermaSolutions also manufactures and distributes the ThermoChem™ HT family of systems and customized procedure kits and disposables to assist in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedures.